← All trials
NCT05775887
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 8, 2023
- Primary completion
- Jun 2, 2023
- Completion date
- Jun 16, 2023
- First posted
- Mar 20, 2023
- Last posted
- Jun 18, 2023
- Enrollment
- 70
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of QueenslandLead sponsor
- Coalition for Epidemic Preparedness InnovationsCollaborator
- Nucleus Network LtdOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.